KCM Investment Advisors LLC Increases Holdings in Eli Lilly and Company $LLY

KCM Investment Advisors LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 14.0% during the third quarter, Holdings Channel reports. The fund owned 24,936 shares of the company’s stock after acquiring an additional 3,059 shares during the quarter. KCM Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $19,026,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. 10Elms LLP grew its holdings in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 10 shares in the last quarter. Bridgewater Advisors Inc. grew its position in Eli Lilly and Company by 0.3% in the 3rd quarter. Bridgewater Advisors Inc. now owns 3,955 shares of the company’s stock valued at $3,018,000 after buying an additional 11 shares in the last quarter. Manske Wealth Management grew its position in Eli Lilly and Company by 2.5% in the third quarter. Manske Wealth Management now owns 448 shares of the company’s stock worth $342,000 after buying an additional 11 shares during the last quarter. Key Client Fiduciary Advisors LLC raised its holdings in shares of Eli Lilly and Company by 1.2% during the third quarter. Key Client Fiduciary Advisors LLC now owns 1,136 shares of the company’s stock valued at $867,000 after acquiring an additional 13 shares during the period. Finally, Darwin Wealth Management LLC increased its stake in shares of Eli Lilly and Company by 3.6% in the third quarter. Darwin Wealth Management LLC now owns 373 shares of the company’s stock worth $285,000 after acquiring an additional 13 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 0.4%

Shares of NYSE LLY opened at $1,004.12 on Thursday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The firm’s 50-day moving average is $1,049.25 and its 200-day moving average is $936.91. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. The firm has a market capitalization of $947.25 billion, a PE ratio of 43.75, a price-to-earnings-growth ratio of 1.17 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The company had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm’s quarterly revenue was up 42.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is 30.15%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly launched the “Lilly Employer Connect” platform to help U.S. employers expand coverage for obesity medicines, offering flexible benefit designs and partnerships with 15+ independent program administrators; company is also offering a Zepbound (tirzepatide) KwikPen single‑patient supply at $449 across doses via the program — this aims to widen patient access while controlling employer costs, supporting uptake and recurring revenue. Lilly Employer Connect platform launches (PRNewswire)
• Positive Sentiment: Lilly confirmed an oral GLP‑1 weight‑loss drug is under evaluation by Australia’s TGA — approval of an oral formulation would broaden prescriber options and patient adoption versus injectables, potentially expanding market share in the fast‑growing obesity/GLP‑1 category. Eli Lilly confirms oral GLP‑1 being evaluated by TGA (AFR)
• Positive Sentiment: EMA issued a positive opinion for Olumiant in alopecia areata — regulatory support broadens Lilly’s immunology portfolio outside metabolic drugs, adding a new commercial avenue and diversification of growth drivers. EMA’s Positive Olumiant Alopecia Opinion (Yahoo Finance)
• Positive Sentiment: Lilly advanced remternetug testing in China and progressed a new oral diabetes candidate in China — clinical expansion in large markets strengthens long‑term neuroscience and diabetes pipelines, important for growth beyond current GLP‑1 momentum. Remternetug testing advances in China (TipRanks)
• Neutral Sentiment: Ventyx Biosciences shareholders approved a merger with Lilly — strategic bolt‑on to strengthen specific capabilities; impact depends on integration and commercialization execution. Ventyx merger approval (TipRanks)
• Neutral Sentiment: Analyst/features pieces (Zacks, 247WallSt, Motley Fool) highlight Lilly as a momentum stock amid GLP‑1 strength but debate whether investors should prefer other long‑term picks — these stories can drive short‑term interest but add little fundamental news. Zacks: Why LLY is a momentum stock

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on LLY shares. Deutsche Bank Aktiengesellschaft lifted their price objective on Eli Lilly and Company from $1,200.00 to $1,285.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Barclays initiated coverage on Eli Lilly and Company in a report on Thursday, February 19th. They set an “overweight” rating and a $1,350.00 price target for the company. Scotiabank restated an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Rothschild & Co Redburn upped their price objective on shares of Eli Lilly and Company from $775.00 to $830.00 and gave the company a “neutral” rating in a research report on Monday, January 26th. Finally, Zacks Research downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,229.59.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.